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Objectives: Isavuconazole, a novel triazole antifungal agent, has broad-spectrum activity against Aspergillus spp.
and other pathogenic fungi. The isavuconazole exposure –response relationship in experimental invasive
pulmonary aspergillosis using galactomannan index (GMI) suppression as a marker of disease clearance
was explored.
Methods: The impact of exposure on GMI suppression in persistently neutropenic rabbits treated with isavuco-
nazonium sulphate (isavuconazole-equivalent dosages of 20, 40 or 60 mg/kg every 24 h, after a 90 mg/kg
loading dose) for 12 days was linked using mathematical modelling. Bridging to humans using population phar-
macokinetic (PK) data from a clinical trial in invasive aspergillosis was performed using Monte Carlo simulations.
Results: Mean plasma isavuconazole AUC/MIC (EC50) of 79.65 (95% CI 32.2, 127.1) produced a half-maximal
effect in GMI suppression. The inhibitory sigmoid Emax curve dropped sharply after an AUC/MIC of ≥30 and
was near maximum (EC80) at 130. Bridging the experimental PK/pharmacodynamic (PD) target to human
population PK data was then used to return to the rabbit model to determine a clinically relevant PD endpoint.
The clinical dosing regimen used in the trial would result in a mean GMI of 4.3+1.8, which is a 50% reduction
from the starting GMI in the experiment.
Conclusions: The clinical trial results showing the non-inferiority of isavuconazole to voriconazole for all-cause
mortality further support the PK-PD endpoint, thereby demonstrating the usefulness of the rabbit model and end-
point for isavuconazole and implications on interpretive breakpoints. Importantly, the analysis supports this
model as an important tool for development of antifungal agents.
Introduction
Isavuconazole is a novel broad-spectrum triazole antifungal
agent, which is available as the prodrug, isavuconazonium sul-
phate, in both intravenous and oral formulations, and which
was recently approved by the US FDA for the primary treatment
of invasive aspergillosis (IA) and mucormycosis in adults.1 IA is
a life-threatening disease that causes significant morbidity and
mortality in patients who are severely immunocompromised.2,3
Isavuconazole is the first agent that has been developed for IA
for 12 years. Despite the recent demonstration of non-inferiority
of isavuconazole compared with voriconazole, there is relatively
little information regarding exposure–response relationships of
isavuconazole against Aspergillus spp., which are required for a
complete understanding of the clinical utility of this agent.
Laboratory animal models that mimic human disease have
long been used to characterize pharmacological efficacy and
safety prior to clinical use. Importantly, well-designed animal
models used in antimicrobial development are generally highly
predictive of clinical efficacy.4 Over the past 20–30 years these
experimental models have enabled an exploration of the relation-
ship between the time-course of drug exposure, penetration of
drug to the site of infection and the ultimate antimicrobial effect.5
The treatment of infections caused by Aspergillus spp. and rare
filamentous fungi is relatively difficult to study in clinical settings.
A detailed understanding of exposure –response relationships
underpins the design of antifungal regimens that are safe and
effective and enables the right dose to be studied the first time.
An understanding of antifungal pharmacokinetic (PK)/pharma-
codynamic (PD) properties also provides the foundation for
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treatment and prevention of antimicrobial resistance, determin-
ation of the requirement for therapeutic drug monitoring and
decision support for establishing in vitro susceptibility breakpoints.
Here, we describe the use of a well-established experimental
rabbit model of invasive pulmonary aspergillosis (IPA) using
serum galactomannan (GM) concentrations as the primary
model readout to characterize the PK/PD relationships of isavuco-
nazole against Aspergillus fumigatus. We were in a unique position
of being able to validate the readout of the experimental PK/PD
model with the clinical findings from the recent Phase 3 clinical
trial. We defined the decrement in GM in the rabbit that is asso-
ciated with clinically relevant exposure of isavuconazole and for
which clinical efficacy has been established. We then reflected
on the PD basis for establishing an in vitro susceptibility interpret-
ive breakpoint of isavuconazole against A. fumigatus.
Materials and methods
Rabbit model of IPA
A previously described persistently neutropenic rabbit model of IPA was
used.6,7 Healthy female New Zealand White rabbits (Covance Research
Products, Inc., Denver, PA, USA) weighing 2.6–3.5 kg were used in the
study. Immunosuppression and profound persistent neutropenia (neutro-
phil concentration of,100 neutrophils/mL) were established by administra-
tion of cytarabine (Ara-C) (Cytarabine injection; Zydus Hospira Oncology
Private Ltd, Gujarat, India for Hospira, Inc., Lake Forest, IL, USA) at an initial
dose of 525 mg/m2 for 5 consecutive days beginning on day 1 of the experi-
ment and a maintenance dose of 484 mg/m2 on days 8, 9, 12 and 13 of the
experiment. Methylprednisolone (Solu-Medrolw, Pfizer for Pharmacia &
Upjohn Co., Division of Pfizer Inc., New York, NY, USA) was dosed at 5 mg/kg
on days 1 and 2.7 Bacterial infection prophylaxis was maintained with anti-
biotics (ceftazidime, gentamicin, vancomycin) as previously described.7
Ethics
Rabbits were monitored under humane care and use of standards in facil-
ities accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care International, according to the guidelines of the
National Research Council for the care and use of laboratory animals,
and under the approval of the Animal Care and Use Committee of Weill
Cornell Medical Center, New York, NY, USA. Rabbits were housed individu-
ally and fed ad libitum.
Organism and MIC
NIH 4215 (ATCC number MYA-1163), which is a well-characterized clinical
isolate of A. fumigatus, was used for all experiments.7 The MICs of voricon-
azole and isavuconazole for A. fumigatus (determined using CLSI standard
M38-A2 broth microdilution methodology) were 0.5 and 1 mg/L, respect-
ively.8 The MICs were measured in triplicate.
Treatment
Rabbits received either prodrug, isavuconazonium sulphate, at an
isavuconazole (BAL4815; active moiety)-equivalent dose of 20 (ISAV20),
40 (ISAV40) and 60 (ISAV60) mg/kg/day or were untreated controls. A
loading dose of the prodrug equivalent to isavuconazole 90 mg/kg was
given on the first day of antifungal treatment to all isavuconazole-treated
rabbits. Treatment was initiated 24 h after inoculation and administered
orally once daily thereafter for up to 12 days. Multiple outcome variables
were analysed from the model, including survival, pulmonary infarct score,
lung weight, residual fungal burden (log cfu/g), serum GM index (GMI),
bronchoalveolar lavage (BAL) fluid GMI and serum (13)-b-D-glucan
levels, as previously described.6
Herein, we report the results of the isavuconazole-treated animals with a
particular focus on the serum GM experiments and PK/PD mathematical
modelling, with a brief description of the primary efficacy results. The primary
efficacy results from the animal model are published elsewhere.6
PD assessment
Blood was collected via the indwelling Silastic catheter at 24 h post-
inoculation, just prior to initiation of antifungal treatment and every
other day thereafter for determination of the serum GM concentrations.
Concentrations were determined by a one-stage immunoenzymatic
sandwich microplate assay method [Plateliaw Aspergillus Enzyme
Immunoassay (EIA), Bio-Rad, Marnes la Coquette, France]9 and according
to the manufacturer’s instructions.
PK
Single-dose PK analyses were conducted in four non-infected rabbits in
each dosage group. Timepoints included pre-dose and 1, 2, 4, 8, 12, 18,
24 and 48 h post-dosing. Multiple-dose PKs were determined in infected
animals 7 days post-inoculation. Blood samples were drawn pre-dose
and at 1, 4, 8 and 24 h post-dosing. Each blood sample for PK assay
was collected in a heparinized syringe. Plasma samples were immediately
separated by centrifugation at 400 g and stored at 2808C until assayed.
Measurement
Isavuconazole was measured using LC/MS/MS. Samples were prepared by
adding 0.1 M paraoxon (10 mL per 1 mL of plasma) to the blank EDTA/K3
and blank Li-heparin rabbit plasma in order to inhibit esterases. Spiking solu-
tions were prepared by serial dilution in DMSO and acetonitrile (ACN), 0.05%
trifluoracetate (TFA) out of a 2 mg/mL stock solution with a range from 0.5
to 500 mg/mL. Calibration samples were performed by spiking 1 mL of each
DMSO (or ACN, 0.05% TFA) solution in 99 mL of blank EDTA/K3 plasma. Each
sample was then quenched with 300 mL of ACN, 0.05% TFA containing 1 mg/
mL BAL0004815-d4, and pyridooxazinone as internal standards.
After centrifugation, 10 mL of the supernatant was injected into the
LC/MS/MS device. A similar preparation method was performed for
the quality control samples; however, blank Li-heparin plasma was used
instead of the EDTA/K3 plasma. For the samples, 50 mL of plasma was
mixed with 150 mL of ACN, 0.05% TFA containing 1 mg/mL BAL0004815-d4
and pyridooxazinone as internal standards, then treated like the calibrators.
Assay linear range was 0.005–4.45 mg/mL and coefficient of variation ranged
from 1.1% to 10.7%. The lower limit of quantification of the plasma assay
was 0.005 mg/mL.
PK and PD mathematical modelling
Mathematical modelling was performed in a step-wise manner. First, a
population PK (PPK) model was constructed using non-parametric estima-
tion in PmetricsTM software (v1.3.2, University of Southern CA, Los Angeles,
CA, USA)10 and fitted to the rabbit plasma concentration data.10 The
weighting functions were estimated using a combination of ADAPT 5
(https://bmsr.usc.edu/software/adapt/; Biomedical Simulations Resource,
Los Angeles, CA, USA) and Pmetrics error estimation runs. Specifically, in
ADAPT 5, slope and intercept values were estimated using maximum
likelihood estimation for each individual rabbit. In Pmetrics, the error esti-
mation run script (i.e. ERRrun) was used to estimate the assay error poly-
nomial coefficients directly from the data. After establishing a model
that best described the PK data, the GM concentrations were added to
the dataset for each individual rabbit. A linked PK/PD model was built
using the following set of differential equations:
dX(1)/dt = −Ka · X(1) (1)
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dX(2)/dt = Ka · X(1) − CL
V
( )
· X(2)
( )
− Kcp · X(2) + Kpc · X(3) (2)
dX(3)/dt = Kcp · X(2) − Kpc · X(3) (3)
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(4)
The first three equations describe the PK of the drug (compartment 1, the-
oretical absorptive compartment for oral administration; 2, central com-
partment; and 3, peripheral compartment). CL is the clearance defined
as the amount of drug being cleared from the central compartment
over time and V is the volume of the central compartment. Ka is the first-
order absorption constant, Kcp is the rate of drug moving from the central
to the peripheral compartment and Kpc is the rate of drug moving from the
peripheral to the central compartment. Equation 4 describes the rate of
change of the serum GM values. Kpmax represents the maximum rate of
production, Hp is the slope function for production, C50p is the amount
of drug where there is half-maximal production, popmax is the theoretical
maximum density of GM, Ksmax is the maximum rate of GM suppression,
C50s is the amount of drug where there is half-maximal suppression
and Hs is the slope function for the GM suppression.
Acceptance of the final model was evaluated by visual inspection
of the observed versus predicted values plotted over time after the
Bayesian step and the coefficient of determination (r2) from the linear
regression of the observed versus predicted values, as well as evaluation
of the estimated bias and precision. After fitting the model to the PK/PD
data, the Bayesian posterior estimates for each rabbit were used to esti-
mate the concentration–time profiles for isavuconazole and GMI for
each rabbit. Simulations were performed in ADAPT 5. AUCs were calculated
by integration from the simulated concentration–time profiles on the last
day of dosing (at steady state) in ADAPT 5.
Using the simulated isavuconazole AUC values and the GMI at the end
of the dosing period for each rabbit, an inhibitory sigmoid Emax model was
constructed to establish the PD relationship between exposure (AUC)
divided by MIC and response (GMI). The model used is described below:
Effect = E0 − Emax · (AUC/MIC)
H
EC50
H + (AUC/MIC)H
( )
(5)
E0 is the baseline level of GM prior to exposure to drug, Emax is the max-
imum GM value, EC50 is a measure of drug potency and H is the slope
factor.
Bridging to humans
To bridge the exposure –response results from the rabbits to humans,
a PPK model was constructed using the isavuconazole plasma concentra-
tion data from the Phase 3 SECURE clinical trial.11 The SECURE
(NCT00412893) trial evaluated the efficacy and safety of isavuconazole
compared with voriconazole in the treatment of patients with possible,
probable or proven IA and other filamentous fungi.11 Patients that were
randomized to isavuconazole received the prodrug, isavuconazonium
sulphate, at a dose of 372 mg every 8 h for the first 2 days followed by
372 mg once daily thereafter [equivalent to isavuconazole at a dose of
200 mg (intravenous) every 8 h for 2 days, then 200 mg once daily]. The
option to receive either intravenous or oral administration was allowed
after day 2. The maximum treatment duration was 84 days. Plasma
trough samples were collected on days 7, 14 and 42, the end of treatment
and at follow-up for some patients. Serial plasma samples (seven in total)
from,25 subjects were collected on day 7 (+1 day) or 14 (+1 day) for PK
profiling. Overall, 113 patients with isavuconazole concentrations were
used for the analysis.
A PPK model using non-parametric estimation was developed in Pmetrics
software (v1.3.2, University of Southern California, CA, USA).10 The model-
fitting process included evaluating both two- and three-compartment
models with and without lag-time and oral bioavailability terms.
Mean Bayesian parameter estimates from the fitted human model
were used to perform Monte Carlo simulations of 1000 patients using
Pmetrics. The simulations were used to calculate steady-state AUCs within
Pmetrics by the trapezoidal rule for each simulated patient. Using Equation
(5) above, the effect of AUC/MIC at various MIC values representative of
the MIC distribution of isavuconazole for A. fumigatus as described by
Espinel-Ingroff et al.12 was calculated.
Total isavuconazole drug levels were used wherever isavuconazole
concentration or AUCs are reported unless otherwise specified.
Results
Animal model
Significant reduction of residual fungal burden, lung weights and
pulmonary infarct score was demonstrated in the two highest
dosage groups (ISAV40 and ISAV60) compared with untreated
controls (P,0.001, ANOVA with Bonferroni’s correction for mul-
tiple comparisons). The highest dose of isavuconazole signifi-
cantly prolonged survival compared with untreated controls
(P,0.001, log-rank test). The lowest dosage (ISAV20) also signifi-
cantly prolonged survival versus untreated controls (P,0.05,
log-rank test).6
Dose-dependent reductions in biomarkers were demonstrated
for isavuconazole-treated animals. ISAV40 and ISAV60 dosage
groups significantly decreased the GMI during therapy following
day 4 compared with increased GMI in the untreated controls
(P,0.01). Figure 1 illustrates GMI versus time for the rabbits trea-
ted with isavuconazonium. BAL GMI was also significantly
reduced in ISAV40 and ISAV60 dosage groups versus untreated
controls (P,0.001, ANOVA with Bonferroni’s correction for mul-
tiple comparisons). Serum (13)-b-D-glucan levels were signifi-
cantly reduced in ISAV40 and ISAV60 compared with untreated
controls (P,0.05, ANOVA with Bonferroni’s correction for multiple
comparisons).6
PK/PD modelling
Visual inspection of the raw concentration–time profile of the
three isavuconazole dosages suggested linear isavuconazole
PK in the rabbit. A two-compartment model with first-order
absorption fitted the rabbit plasma isavuconazole drug concen-
tration data well. The fit of the linked PK/PD model was also
acceptable based on a coefficient of determination for the
observed versus predicted values after the Bayesian step of
0.965 and 0.895 for the PK concentrations and GMI, respectively
(Figure 2). The estimates of bias and precision for the rabbit PK
were20.14 and 1.05, and20.288 and 0.892 for GMI, respectively.
Parameter estimates from the final model are summarized in
Table 1.
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The exposure–response relationship showed that the GMI
responded sharply for AUC/MIC of ≥30 (Figure 3). The AUC/MIC
that induced the half-maximal effect (EC50) was estimated at
79.65 (95% CI 32.2, 127.1), which resulted in a 50% reduction
in GMI. Suppression of GMI was a near maximum (EC80) at an
AUC/MIC of 130.
Bridging to humans
Human isavuconazole plasma drug concentrations from the
Phase 3 SECURE clinical trial in patients with IA or other filament-
ous fungi were used to construct a non-parametric PPK model
using Pmetrics software.10 A two-compartment model with first-
order absorption fitted the data well, with a coefficient of deter-
mination after the Bayesian step of 0.877. Visual inspection of
the observed versus predicted values was acceptable, as were
measures of bias and precision. The mean parameter estimates
from the PPK model for the Phase 3 human plasma concentra-
tions are presented in Table 2.
Monte Carlo simulations using the mean parameter estimates
from the human PPK model were performed. The AUCs for
1000 simulated patients were estimated using the linear tra-
pezoidal rule in the makeAUC function within Pmetrics. The
mean steady-state AUC+SD for the simulated population was
82.6+33.0 mg h/L. The corresponding drop in GMI in rabbits
receiving human-like exposures of isavuconazole was 4.3+1.8,
which closely approximates the EC50 for GMI reduction (4.1 GMI
units) from the start of the experiment in the rabbits (E0¼8.2).
After Monte Carlo simulations of 1000 patients, the effect of
AUC/MIC at different MIC values relevant to the WT MIC distribu-
tion of A. fumigatus for isavuconazole as tested by CLSI method-
ology is displayed in Figure 4. The figure illustrates the predicted
GMI at the end of the experiment given the inherent PK variability
in humans as a function of each MIC value following the adminis-
tration of the regimen of isavuconazonium sulphate that was
used in the recent clinical trial.
Discussion
Isavuconazole is a novel triazole antifungal agent that is adminis-
tered as the water-soluble prodrug isavuconazonium sulphate.
This novel agent demonstrated non-inferior efficacy (as defined
by upper bound of the 95% CI less than the pre-specified 10%
non-inferiority margin) compared with voriconazole for all-cause
mortality up to day 42 (18.6% versus 20.2%, intent-to-treat popu-
lation) in the SECURE trial for the treatment of IA and invasive
disease caused by other filamentous fungi.11
The clinical trial results enable a retrospective validation of the
clinical validity of the endpoints used in the experimental PK/PD
model. An isavuconazole AUC that has been associated with
clinical efficacy that is at least as good as the current standard
of care (i.e. voriconazole) induces a 50% reduction in circulating
GM concentrations in the persistently neutropenic rabbit model
of IPA. Thus, the rabbit model as currently designed produces
an ‘on-scale’ readout that appears clinically relevant and tract-
able. These analyses provide a unique opportunity to evaluate
the predictive nature of the rabbit model endpoints and further
facilitate the use of this model for the future development of
new antifungal agents.
The findings in this study also have implications for setting
in vitro susceptibility breakpoints for isavuconazole against
A. fumigatus. The recent clinical study (SECURE) clearly suggests
that isavuconazole is an effective agent for the treatment of IA.
If an assumption is made that the vast majority of isolates in
the clinical trial are WTorganisms, then A. fumigatus is considered
to be a ‘good target’ for isavuconazole. In the absence of other
clinical or PD data, the breakpoint for isavuconazole against
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Figure 1. GMI versus time for each rabbit after administration of
isavuconazonium sulphate (all dose groups).
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Figure 2. Regression plot of observed (y-axis) versus model predicted (x-axis) plots from rabbit isavuconazole PPK (a) and GMI (b).
Kovanda et al.
1888
A. fumigatus is ordinarily set at the epidemiological cut-off value
(ECV or ECOFF), which is ≤1 mg/L.12 There is no evidence from the
SECURE study that there is a relationship between MIC and clinical
outcome, although the number of patients with a positive culture
was too small to enable a definitive analysis. This PD study pro-
vides a further perspective on the validity of using 1 mg/L as a
breakpoint. Without making any assumptions about a GMI cut-off
value that defines therapeutic success and failure, Figure 4 shows
the predicted GMI values for patients receiving a standard clinical
isavuconazole regimen and infected with isolates with a range of
MICs. The histograms in Figure 4 suggest that a≥50% reduction in
GMI is achieved for isavuconazole MICs ,1 mg/L. Similarly, GM
antigen expression is not suppressed in patients with an MIC
≥2 mg/L. For an MIC of 1 mg/L some patients have suppressed
GM antigen expression while others do not. Therefore, an MIC of
1 mg/L may on occasions be difficult to treat and be therefore
classified as intermediate to denote the fact that isavuconazole
should be used with some caution in this situation.
The PK/PD relationship for isavuconazole against Aspergillus
spp. has been described for a variety of other experimental designs;
however, given the results of the clinical trial, not all appear to pre-
dict the clinical response for isavuconazole well. Therefore, it is
important to understand the key differences between the models
and how these differences may have an impact on the develop-
ment of a new antifungal drug. Lepak et al.13 used a neutropenic
murine model of IPA. The model used a diverse group of organisms
(10 in total) ranging from WT organisms to organisms with well-
characterized cyp51a point mutations. In contrast to the current
model, primary efficacy was defined by the net stasis in fungal
growth as measured by the density of fungal DNA in the lung.
The estimated total drug PD target (AUC/MICCLSI) from this experi-
ment was 503. In contrast, Seyedmousavi et al.14 evaluated isavu-
conazole in a non-neutropenic mouse model of disseminated
aspergillosis. Similar to the model of Lepak et al.,13 this model uti-
lized both WTand cyp51amutants. However, the primary outcome
measure was 14-day survival. The total drug AUC/MICCLSI target
associated with 50% survival (EC50) was 10-fold lower and esti-
mated to be 50.
The estimated half-life of isavuconazole in rabbits (17.5 h) is
significantly longer than in mice (1–5 h).13 The difference in half-
life between the two animal models could have an impact when
estimating the PD target in severe experimental conditions (e.g.
profound and prolonged neutropenia). The relative absence of
neutrophils combined with long periods of the dosing interval
where drug concentrations are beneath a critical threshold may
enable fungal regrowth. Progressively higher dosages of isavuco-
nazole are then required to achieve concentrations that prevent
fungal regrowth. It is therefore possible that the rapid clearance
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AUC/MIC (x-axis) and the associated terminal GM value (y-axis).
The black squares represent the observed GMI value for each rabbit
(+SEM). The continuous black line represents the fit of the inhibitory
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Table 1. Mean and SD values for each parameter estimated from the
rabbit PPK/PD-linked model
Parameter (units) Mean SD
Ka (h
21) 20.145 8.842
CL/F (L/h) 1.108 1.228
V/F (L) 27.911 6.872
Kcp (h
21) 5.953 2.498
Kpc (h
21) 6.394 2.916
Kpmax (GMI/h) 0.115 0.047
Hp 17.220 4.116
C50p (mg/L) 1.286 1.548
IC (GMI) 0.108 0.053
Ksmax (GMI/h) 0.009 0.002
Hs 12.292 5.029
C50s (mg/L) 0.167 0.127
popmax (GMI) 6.642 2.324
Ka, first-order rate constant describing the movement of drug from the gut
to the central compartment; F, bioavailability; IC, initial condition of GMI
prior to drug exposure; Kcp, rate of drug moving from the central to the
peripheral compartment; Kpc, rate of drug moving from the peripheral to
the central compartment; Kpmax, maximum rate of GM production; Hp,
slope function for GM production; C50p, amount of drug where there is
half-maximal production; popmax, theoretical maximum density of GM,
Ksmax, maximum rate of GM suppression; C50s, amount of drug where
there is half-maximal suppression; Hs, slope function for the GM
suppression.
Table 2. Mean and SD values for each parameter estimated from the
human PPK model
Parameter (units) Mean SD
Ka (h
21) 24.3 16.7
CL (L/h) 2.2 1.1
V (L) 398.8 225.2
F (%) 90.2 20.9
Tlag (h) 1.5 3.3
Ka, first-order rate constant that describes the movement of drug from the
gut to the central compartment; F, bioavailability; Tlag, lag time.
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of drug, the use of dosing intervals (every 12 h) that are many
multiples of the half-life and the severe nature of the model con-
spire to produce an inaccurate estimate of the drug exposure that
is ultimately required for therapeutic efficacy.
In addition to the animal models described above, an in vitro
human alveolus model of experimental pulmonary aspergillosis
was conducted.15 The total drug AUC/MIC estimated for this sys-
tem was 11. This lower value probably largely reflects the finding
that the model best simulates early (first 24 h) versus more
established disease (.24 h).16 The in vitro alveolus model also
does not reflect the tissue injury, including haemorrhagic infarc-
tions, which may impair penetration of the antifungal agent to
the invading hyphae. These factors are important determinants
of the drug exposure required to suppress circulating GM antigen
concentrations.
When one considers the possible use of these PD targets in
drug development, it is clear that even small differences may
have a significant impact on the regimen that is ultimately chosen
and the establishment of in vitro susceptibility breakpoints. For
example, use of the PD target defined in the neutropenic mouse
model would have placed the isavuconazole breakpoint in the
middle of the WT population (at 0.06 mg/L), which is neither
ideal nor consistent with clinical trial findings. A corollary is that
a much higher dose would have been predicted to be successful
than was ultimately used in the clinical trial. The rabbit model pro-
vides ‘on-scale readouts’ for isavuconazole and a clinically rele-
vant model readout of a 50% reduction in GMI. Thus, complete
suppression of GM antigen, which may be desirable when treating
a patient with IA, is not a relevant consideration for PK/PD bridging
studies (in the same way that 100% survival may not be possible
or reasonable). Therefore, all the preclinical PK/PD studies for
isavuconazole and the subsequent bridging studies provide
a salutary lesson in the use of PK/PD models for drug develop-
ment. Orthogonal reasoning should be applied, models must be
stressed, positive controls should be used to benchmark model
performance and readouts, and findings should be repeatedly
cross-checked.
This study has several limitations. First, only one WT organism
of A. fumigatus was used in the experimental model. A more
diverse group of organisms with a range of MICs, including
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Figure 4. Frequency distribution of terminal GM values at each MIC value. Monte Carlo simulation of 1000 subjects after exposure to the clinical dosing
regimen of isavuconazonium sulphate.
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organisms with well-characterized resistance mechanisms, would
provide a more robust assessment of the exposure–response rela-
tionship. Second, the experimental findings as presented are only
relevant to CLSI methodology. Third, a small number of terminal
GMI values fall in the middle of the curve, suggesting that the
results could be driven by the majority of values that occur at the
extremes of effect or no effect. Nevertheless, this study provides
further evidence that GM is a robust clinically relevant biomarker
that can be used to characterize the PD of anti-Aspergillus agents.
A 50% reduction in GMI in this persistently neutropenic rabbit
model of IPA correlates well with the results of the Phase 3 clinical
trial for isavuconazole, which provided a foundation to further char-
acterize the PD of new antifungal agents and the selection of new
regimens for study in early-phase clinical trials.
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